Cost-effectiveness analysis of regorafenib dose optimization for refractory metastatic colorectal cancer
ReDO was cost-effective compared with TAS-BEV from the US payer's perspective despite a higher QALY gain associated with TAS-BEV. ReDO was dominant over fruquintinib, consistently having a higher QALY gain and lower cost.
Authors
- Woojung Lee (ORCID: https://orcid.org/0000-0003-4878-9082)
- Marisca Marian
- Svetlana Babajanyan (ORCID: https://orcid.org/0000-0002-5910-5988)
- Brian Hocum
- Sang Kyu Cho (ORCID: https://orcid.org/0000-0002-7795-1328)
- Tanios Bekaii‐Saab (ORCID: https://orcid.org/0000-0001-7721-1699)
- Afsaneh Barzi (ORCID: https://orcid.org/0000-0002-0032-2988)
- Jamie Partridge Grossman (ORCID: https://orcid.org/0000-0001-9358-8971)
- Sreevalsa Appukkuttan (ORCID: https://orcid.org/0000-0003-2537-1687)
- Min Yang (ORCID: https://orcid.org/0000-0002-4864-6658)
Institutions
- Bayer (United States) (US)
- WinnMed (US)
- City of Hope (US)
- Analysis Group (United States) (US)
Publication Details
- Journal
- Journal of Medical Economics
- Published
- 2025-04-23
- DOI
- https://doi.org/10.1080/13696998.2025.2496068
- Primary Topic
- Colorectal Cancer Treatments and Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00